Table 3.

Univariate and multivariate analysis of the relationship between disease specific survival and clinicopathologic characteristics in patients with TCGA.

Characteristics	Total number (N)	HR (95% CI)	P value
A
Age (>65 vs. <=65)	459	1.039 (0.713-1.513)	0.842
Gender (Female vs. Male)	469	1.046 (0.720-1.519)	0.815
Smoker (Yes vs. No)	455	1.013 (0.585-1.755)	0.962
number pack years smoked (>=40 vs. <40)	318	0.904 (0.569-1.437)	0.67
T stage (T2-4 vs. T1)	466	1.747 (1.125-2.714)	0.013
N stage (N1-3 vs. N0)	457	2.795 (1.919-4.071)	<0.001
M stage (M1 vs. M0)	327	2.480 (1.278-4.811)	0.007
Pathologic stage (Stage II-IV vs. Stage I)	461	3.519 (2.350-5.271)	<0.001
Primary therapy outcome (PD vs. SD-CR)	408	5.929 (3.981-8.830)	<0.001
TP53 status (Mut vs. WT)	465	1.335 (0.920-1.937)	0.128
CDCA4 (High vs. Low)	469	1.823 (1.243-2.675)	0.002
B
Pathologic stage (Stage II-IV vs. Stage I)	461	2.885(1.868-4.456)	<0.001
Primary therapy outcome (PD vs. SD-CR)	408	5.145(3.413-7.758)	<0.001
CDCA4 (High vs. Low)	469	1.674(1.112-2.521)	0.014